Paul Watt - Phylogica Limited Insider

Phylogica Limited -- Australia Stock  

AUD 0.04  0.00  0.00%

Chief Scientific Officer

Dr. Paul Michael Watt is NonExecutive Director of Phylogica Ltd. He is a graduate from The University of Western Australia. He completed his doctorate in Molecular Biology at Oxford University before taking up postdoctoral appointments in yeast genetics at Harvard and Oxford Universities. He discovered three novel genes, including the yeast homologue of the human Bloom and Werner syndrome genes involved in cancer susceptibility. He is an Honorary Research fellow at the Telethon Institute for Child Health Research and an Adjunct Professor at the school of Paediatrics and Child Health of the University for Western Australia. Dr. Watt has published more than 45 peer reviewed scientific papers. Dr. Watt has more than 12 years experience in commercializing intellectual property and is the primary inventor on 20 patents. He founded InfaMed Ltd., now owned by Avita Medical Ltd.
Age: 47  Executive Since 2016      
61 8 9489 7777  http://www.phylogica.com.au

Management Efficiency

The company has return on total asset (ROA) of (30.17) % which means that it has lost $30.17 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (26.56) % meaning that it generated substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Clayton WhippInsurance Australia Group Limit
2015
Ian KemishNewcrest Mining Limited
2016
Amanda StreetTransurban Group
2011
Julie BatchInsurance Australia Group Limit
2015
Leona MurphyInsurance Australia Group Limit
2011
Amanda RevisSuncorp Group Limited
2016
Geoffrey DayNewcrest Mining Limited
2014
Christopher BertuchInsurance Australia Group Limit
2011
Alex HarrisonInsurance Australia Group Limit
2015
Michele HueyTransurban Group
2014
Sarah HarlandSuncorp Group Limited
2016
Andrew HeadTransurban Group
2011
Melanie AllibonNewcrest Mining Limited
2017
Tony AdamsTransurban Group
2014
Mark ReinkeSuncorp Group Limited
2016
Robert GerrardBrambles Limited
2017
Lisa TobinTransurban Group
2013
Anna LenahanSuncorp Group Limited
2013
Rebecca FarrellInsurance Australia Group Limit
2017
Jane ThomasNewcrest Mining Limited
2016
Craig OlsenInsurance Australia Group Limit
2016

Entity Summary

Phylogica Limited offer drug discovery research and development services utilizing proprietary Phylomer peptide libraries and screening methodologies to identify peptide drug candidates for its pharmaceutical and biotechnology partners in Australia. Phylogica Limited (PYC) is traded on Australian Securities Exchange in Australia. It is located in Subiaco, WA and employs 5 people.

Did you try this?

Run Money Managers Now
   

Money Managers

Screen money managers from public funds and ETFs managed around the world
Hide  View All  NextLaunch Money Managers
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Phylogica Limited to your portfolio

Top Management

Phylogica Limited Leadership Team
Douglas Wilson, Chairman, Ph.D
Bernard Hockings, Director, Ph.D
Paul Watt, Executive
Sahm Nasseri, Director, MBA
Kevin Hart, CFO
Graeme Boden, CFO, CPA
Rudi Michelson, Executive
Rick Kendall, Director, Ph.D
Stephanie Unwin, Director
Robert Hayes, Director, Ph.D
Bruce McHarrie, Director
Natasha Forde, Executive
Richard Hopkins, CEO
Jeremy CurnockCook, Director
Rohan Hockings, Director

Stock Performance

Phylogica Limited Performance Indicators